X
|
STUDENT DIGITAL NEWSLETTER ALAGAPPA INSTITUTIONS |
|
Alfonso Casta, MD
Follow-up ultrasound examination in the second trimester is essential to assess fetal anatomy in more detail erectile dysfunction natural supplements trusted top avana 80mg. Hyperechogenic Kidneys Definition the term "hyperechogenic kidneys" is used in the second trimester to describe increased echogenicity of the renal parenchyma impotence test buy top avana 80 mg low price, typically with renal tissue appearing more echogenic than the surrounding liver erectile dysfunction doctor omaha cheap top avana 80mg with amex. As stated in the section on normal anatomy erectile dysfunction for young men top avana 80mg with visa, the kidneys appear slightly more echogenic in the first trimester than later on in pregnancy. There is currently no objective definition on what represents hyperechogenic kidneys in the first trimester, and the diagnosis is based on subjective assessment of experienced operators. Indeed, improvement in ultrasound technology has resulted in improved tissue characterization in the first trimester and, in some cases, in increased echogenicity of kidneys. The suspicion of hyperechogenic kidneys is particularly relevant in pregnancies at high risk for renal disease because of the presence of additional ultrasound signs. As in the second trimester, hyperechogenic kidneys can be a transient finding, but may also be a marker for renal abnormalities. Detailed sonographic evaluation of the fetus and follow-up examinations are recommended when hyperechogenic kidneys are noted in the first trimester of pregnancy. Increased echogenicity of fetal kidneys in the first trimester can be a sign of associated renal dysplasia, aneuploidy, or cystic renal disease. A and B: Hyperechogenic kidneys (arrows) in the first trimester in association with posterior urethral valves. C and D: Hyperechogenic kidneys (arrows) in the first trimester in association with trisomy 13. Facial dysmorphism, cardiac anomaly, and other abnormalities were also seen on ultrasound (not shown). Note in B, the presence of hyperechogenic kidneys, a common finding in trisomy 13. Note the presence of bilaterally enlarged polycystic kidneys, seen transabdominally in A and C and transvaginally in B. D: An axial plane of the lower pelvis in color Doppler shows the two umbilical arteries with no bladder seen in between. Amniotic fluid is still normal at this gestation and typically disappears around 16 weeks. This pregnancy was the result of consanguineous couple with recurrence risk of 25%. Note in A the presence of an occipital encephalocele and in B the presence of bilateral polycystic kidneys (arrows). B: A coronal plane of the abdomen in the next pregnancy at 12 weeks of gestation, showing normal size kidneys (one shown-arrow) with mild hyperechogenicity: within the echogenicity range of normal kidneys in early gestation (compare with. Ultrasound Findings Ideally, the kidneys should be visualized in a sagittal or coronal view in order to demonstrate large segments of renal parenchyma and enable a comparison with the surrounding lung, liver, and bowel. Enlarged hyperechogenic kidneys in the first trimester are particularly concerning because of the possibility of polycystic kidney disease or the association with aneuploidies. Out of the ciliopathies group is MeckelGruber syndrome, with the triad of polycystic kidneys, encephalocele, and polydactyly. When normal or mildly hyperechogenic kidneys are noted in the first trimester in at-risk families, follow-up ultrasound examinations into the second and third trimester is important because progression of ultrasound findings tend to occur after mid-gestation. The presence of enlarged hyperechogenic kidneys can occasionally be seen in early gestation, typically in the presence of a family history. The presence in the first trimester of an absent bladder on repeated examinations is also possible, given the lack of renal function. Bilateral Renal Agenesis Definition Bilateral renal agenesis is defined by the congenital absence of both kidneys and ureters, and results from a developmental failure of the ureteric bud and/or the metanephric mesenchyme. Bilateral renal agenesis has a prevalence of 1:4,000 to 1:7,000 pregnancies at the routine obstetric ultrasound examination. Anhydramnios leads to Potter sequence, which is a constellation of findings including pulmonary hypoplasia, facial abnormalities, and deformities of extremities. Bilateral renal agenesis is more common in males and is a uniformly lethal malformation. Ultrasound Findings the prenatal diagnosis of bilateral renal agenesis is a straightforward diagnosis after 16 weeks, because of associated oligohydramnios, as a leading ultrasound clue. The onset of oligo- or anhydramnios starts between 15 and 16 weeks of gestation when amniotic fluid production is primarily renal in origin. Therefore, the suspicion of bilateral renal agenesis in the first trimester is a challenge and primarily relies on the identification of an absent bladder and kidneys. Absent bladder in the pelvis on repeated ultrasound examinations may alert the examiner to the presence of bilateral renal agenesis in the first trimester. On rare occasions, a small "bladder" maybe visible in the pelvis in early gestation despite the presence of bilateral renal agenesis. Although the exact etiology of this finding is currently unclear, possibilities include retrograde filling of the bladder or the presence of a midline urachal cyst mimicking the bladder. The "lying down" or "flat" adrenal sign, an important second trimester sign showing the flattened adrenal gland on the psoas muscle, is not easily seen in the first trimester. When bilateral renal agenesis is suspected in the first trimester, follow-up ultrasound in the early second trimester is recommended to confirm the diagnosis by the onset of anhydramnios. Associated Malformations Associated malformations have been frequently reported and include gastrointestinal, vascular, and laterality defects. Chromosomal aneuploidy is present in about 7% of prenatal cases,27 and several causative gene mutations have been described. The absence of a bladder on ultrasound in the first trimester should also alert the examiner to the presence of other urogenital malformations such as bladder exstrophy or bilateral cystic renal dysplasia. In B, renal arteries could not be imaged with empty renal fossa and absence of renal arteries bilaterally. The presence of a pelvic kidney could not be ruled out, and the patient had a follow-up ultrasound at 16 weeks of gestation (not demonstrated) showing anhydramnios and confirming the diagnosis of bilateral renal agenesis. Note the presence of the typical flat adrenal gland (labeled) in A and B and compare with the normal shape of the adrenal gland in Figure 13. Fetus in A also had a single umbilical artery, which led us to perform a transvaginal detailed ultrasound. Fetus in B had a cardiac defect, diagnosed at 12 weeks of gestation and detailed first trimester ultrasound revealed the presence of an empty renal fossa with flat adrenal gland (asterisk). Unilateral Renal Agenesis Unilateral renal agenesis results when one kidney fails to develop and is absent. This is primarily because of failure of development of the ureteric bud or failure of induction of the metanephric mesenchyme. The prenatal diagnosis in the first trimester is initially suspected when one kidney is not seen in the renal fossa. A search for a pelvic kidney or crossed ectopia should be performed before the diagnosis of unilateral renal agenesis is confirmed. Color Doppler of the abdominal aorta, obtained in a coronal plane of the abdomen and pelvis, is helpful to confirm the diagnosis because it shows the absence of a renal artery on the suspected renal agenesis side. In highresolution ultrasound, visualization of the renal fossa can reveal the presence of the horizontal flat (lying down) adrenal gland instead of the kidney. Compensatory hypertrophy of the contralateral kidney is present in the second and third trimester of pregnancy. The diagnosis of a single umbilical artery in the first trimester presents an increased risk for renal malformations. Pelvic Kidney, Crossed Renal Ectopia, and Horseshoe Kidney Abnormal kidney location, also referred to as renal ectopia, encompasses three types of abnormalities: pelvic kidney, crossed renal ectopia, and horseshoe kidney. Abnormal kidney location results from failure of proper migration of the metanephros from the pelvis to the abdomen during embryogenesis. Pelvic kidney refers to a kidney that is located in the pelvis below the aortic bifurcation. Crossed renal ectopia refers to two kidneys on one side of the abdomen, with fusion of the kidneys. Horseshoe kidney, the most common form of renal ectopia, refers to fusion of the lower poles of the kidneys in the midline abdomen, typically below the origin of the inferior mesenteric artery. In the first trimester, the slightly bright appearance of kidneys helps in the identification of kidney location in the pelvis when the renal fossa appears empty. Bridging of renal tissue over the fetal spine helps in the identification of a horseshoe kidney in the first trimester. In our experience, the presence of trisomy 18, Turner syndrome, and single umbilical artery increases the risk for an association with horseshoe kidneys.
It is therefore extremely unlikely that these agents would differ in the adjuvant setting erectile dysfunction doctors minneapolis purchase top avana 80 mg line, and statements regarding cetuximab in this setting may be reasonably applied to panitumumab erectile dysfunction causes in early 20s generic top avana 80 mg without prescription. Using Medicare billing records reasons erectile dysfunction young age buy cheap top avana 80 mg on-line, they identified those patients who did or did not receive chemotherapy within 3 months of operation erectile dysfunction natural remedies over the counter herbs purchase 80mg top avana with mastercard. Their review identified that 27% of patients received chemotherapy during the 3-month postoperative period. Younger age, white race, unfavorable tumor grade, and low comorbidity were associated with a greater likelihood of receiving treatment. The 5-year survival was 75% for untreated patients and 78% for those patients who received therapy in this nonrandomized comparison. This absolute difference of 2% closely approached, but did not reach, statistical significance. While the review has substantial flaws that limit interpretation of these results, it does indicate that larger, higher-quality trials are warranted. Investigators will seek to identify "high-risk factors of recurrence/death" as well as predictors of efficacy and toxicity in the adjuvant arm. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. More recently, a genetic profiling assay utilizing 21-gene signature analysis has become available. However, there was no interaction with treatment, meaning that the test is prognostic, identifying relatively lower or higher risk individuals, but it provided no guidance on whom to treat. Thus, despite the interesting data outlined in the following, it would appear to be of little value in decision making at this time. Despite this limitation, research efforts have been increasingly focused on developing and refining such gene signatures over the past few years, with three that stand out presently, promising to improve and possibly replace current risk stratification models. It also appears to better classify high-risk patients than clinicopathologic factors alone. While the signature has been validated twice in retrospective trials, it is not yet available for commercial use. Cape/Ox is also an acceptable alternative in appropriately motivated and reliable patients. The risk of peripheral neuropathy and the possibility of long-term neuropathy must be considered in the selection of therapy. The long-term morbidity of oxaliplatin treatment has become more appreciated; however, it is anticipated that risk stratification strategies may become available in the near future to identify those patients who are likely to benefit from oxaliplatin treatment. Irinotecan-based regimens should not be used in the adjuvant setting, as randomized data have shown increased toxicity and no long-term benefit. Bevacizumab, cetuximab, and panitumumab should also not be used in the adjuvant setting, as they add toxicity and expense, and do not add benefit. However, this time frame is somewhat arbitrary, based largely on what has been mandated in clinical trials. As such, these findings should be regarded as hypothesis-generating only, and certainly not definitive. An ideal immunologic target molecule would be a highly antigenic epitope that is always expressed on the tumor and never expressed on normal tissue. Such an ideal target has yet to be identified; however, a number of approaches have been explored. Thus, a number of avenues of investigation are being pursued; however, at this time the use of vaccine therapy for treatment of resected colon cancer remains highly investigational. A vaccine based on this antigen was found to be highly immunogenic in the premalignant setting, inducing long-term memory responses and no significant toxicity when administered to patients with advanced colonic adenomas. Subsequent studies will determine whether these results translate into meaningful clinical outcomes. Similar findings were reported from a 533 patient trial performed by the Swiss Group for Clinical Cancer Research. Subsequently, a large meta-analysis of intraportal chemotherapy trials involving over 4,000 patients in 10 randomized studies revealed only a 4% improvement in 5-year overall survival for the patients who received portal infusion. At present, intraportal adjuvant chemotherapy has not been accepted as routine practice and remains limited to clinical investigations. Active Specific Immunotherapy Irradiated cancer cells maintain their immunogenicity; however, they are unable to proliferate. Active specific immunotherapy is a maneuver in which patients are immunized with a preparation of their own irradiated tumor cells plus an immunostimulant such as bacillus Calmette-Guйrin. Overall, trials have failed to show a benefit for the use of active specific immunotherapy in the management of colon cancer, and its use should remain limited to investigational settings. Preoperative Chemotherapy Investigators are currently exploring the role of preoperative chemotherapy in the management of nonmetastatic disease. This small trial is encouraging but would require further corroboration before being accepted into standard practice. Hyperthermic intraperitoneal chemotherapy has been explored as a possible means of providing a benefit in patients at high risk for developing peritoneal metastases. Large randomized trials would be necessary, however, before nonresearch use of this highly aggressive and potentially toxic treatment strategy could be considered. There were no significant differences in postoperative morbidity between the two groups. While a small proportion of the patients receiving preoperative therapy had apparent progression during the time between staging and surgery, there were no tumor-related complications during this interval. Overall, preoperative therapy resulted in significant downstaging, including reductions in apical node involvement and incomplete resections as well as two pathologic complete responses. Whether these results will translate into improved survival and potentially change the accepted pathway for management of nonmetastatic disease remains to be seen. A larger phase 3 trial now under way will hopefully shed light on this issue in the near future. Second, surveillance may increase the chance of identifying local regional or distant recurrence that is potentially curable by surgery. It should be noted that it is this detection of potentially curable recurrent or second primary disease that justifies routine postoperative surveillance. To date, there are no compelling data that indicate that early detection of unresectable asymptomatic metastatic disease is of benefit to the patient. In other words, if recurrent disease is unresectable and therefore incurable, there is no urgency to identify it; there is no compelling evidence that the early initiation of palliative chemotherapy is of benefit in the asymptomatic, incurable patient. Although the choice of follow-up routine and which studies to include in that follow-up have been the subject of much debate in the colon cancer literature,292295 subsequent analyses have shown that most interventions that have been considered are not value-added and not appropriate for routine use. Colonsocopy is recommended at 1 year after resection (or 3 to 6 months after resection if a complete colonoscopy was not performed prior to surgery) and then 3 years later, and then every 5 years. Of note, older studies advocating routine monitoring of complete blood count, liver function studies, lactate dehydrogenase, chest X-rays, and fecal occult blood monitoring have not been supported by subsequent data, and none of these are recommended for routine monitoring of patients at this time. A second surgeon participated in the remainder of the exploration after thoroughly reviewing all studies including the nuclear medicine scans. The middle and far panels show the same region imaged with fluorodeoxyglucose position emission tomography. Therefore, while not in itself substantiated by the data in the literature, it is felt that routine postresection visits be performed every 3 to 6 months for the first 3 years following resection and every 6 months during years 4 and 5. The role of liver function tests as a means for detecting colorectal recurrence has also been carefully evaluated. Routine fecal occult blood testing, routine complete blood counts, and routine chest X-rays were all not thought to be of benefit in postoperative surveillance. With respect to colonoscopy and flexible proctosigmoidoscopy, the panel, after reviewing the literature, recommended that all patients have a colonoscopy for the pre- or perioperative documentation of the cancer and to ascertain that the remainder of the colon is free from polyps. Further, the panel agreed that the data were sufficient to recommend colonoscopy at 3 years to detect new cancers and polyps and then every 5 years if normal. Further, the panel concluded that colonoscopy was superior to flexible proctosigmoidoscopy and therefore should be performed as previously discussed for patients following both colon and rectal cancer surgery. All five studies had a control arm subjected to a less aggressive follow-up regimen, which varied from study to study ranging from no specific follow-up to interval laboratory tests and plain X-rays or ultrasound. Lesions found on colonoscopy should be managed appropriately either with colonoscopic resection or surgical management. These surveillance guidelines should allow for the early detection of either resectable recurrence or second primary lesions and therefore the potential to impact patient outcome. Resection of locoregional recurrence can also benefit the patient with respect to local control and overall outcome.
Binding of substrate to one site then enhances the affinity of the remaining sites to bind additional substrate erectile dysfunction kaiser generic top avana 80mg with visa. The greater the value for n 2010 icd-9 code for erectile dysfunction order 80mg top avana, the higher the degree of cooperativity and the more markedly sigmoidal will be the plot of vi versus [S] erectile dysfunction caused by steroids purchase top avana 80mg mastercard. A perpendicular dropped from the point where the y term log vi/(Vmax - vi) is zero intersects the x-axis at a substrate concentration termed S50 purchase erectile dysfunction drugs buy top avana 80mg cheap, the substrate concentration that results in half-maximal velocity. The effects of competitive inhibitors can be overcome by raising the concentration of substrate. Most frequently, in competitive inhibition the inhibitor (I) binds to the substrate-binding portion of the active site-thereby blocking access by the substrate. The structures of most classic competitive inhibitors therefore tend to resemble the structures of a substrate, and thus are termed substrate analogs. Inhibition of the enzyme succinate dehydrogenase by malonate illustrates competitive inhibition by a substrate analog. Succinate dehydrogenase catalyzes the removal of one hydrogen atom from each of the two methylene carbons of succinate (Figure 89). However, since malonate contains only one methylene carbon, it cannot undergo dehydrogenation. The strength of the interaction between an inhibitor and an enzyme depends on the forces important in protein structure and ligand binding (hydrogen bonds, electrostatic interactions, hydrophobic interactions, and van der Waals forces; see Chapter 5). Inhibitors can be classified on the basis of their site of action on the enzyme, on whether they chemically modify the enzyme, or on the kinetic parameters they influence. Compounds that mimic the transition state of an enzyme-catalyzed reaction (transition state analogs) or that take advantage of the catalytic machinery of an enzyme (mechanism-based inhibitors) can be particularly potent inhibitors. Kinetically, we distinguish two classes of inhibitors based upon whether raising the substrate concentration does or does not overcome the inhibition. The extent to which [S] must be increased to completely overcome the inhibition depends upon the concentration of the inhibitor present, its affinity for the enzyme, Ki, and the affinity, Km, of the enzyme for its substrate. For classic competitive inhibition, the lines that connect the experimental data points converge at the y-axis (Figure 810). Since the y intercept is equal to 1/Vmax, this pattern indicates that when 1/[S] approaches 0, vi is independent of the presence of inhibitor. Note, however, that the intercept on the xaxis does vary with inhibitor concentration-and that since -1/Km is smaller than 1/Km, Km (the "apparent Km") becomes larger in the presence of increasing concentrations of the inhibitor. Thus, a competitive inhibitor has no effect on Vmax but raises Km, the apparent Km for the substrate. More complex noncompetitive inhibition occurs when binding of the inhibitor does affect the apparent affinity of the enzyme for substrate, causing the lines to intercept in either the third or fourth quadrants of a double-reciprocal plot (not shown). While certain inhibitors exhibit characteristics of a mixture of competitive and noncompetitive inhibition, the evaluation of these inhibitors exceeds the scope of this chapter. Dixon Plot A Dixon plot is sometimes employed as an alternative to the Lineweaver-Burk plot for determining inhibition constants. The initial velocity (vi) is measured at several concentrations of inhibitor, but at a fixed concentration of substrate (S). For a simple competitive or noncompetitive inhibitor, a plot of 1/vi versus inhibitor concentration [I] yields a straight line. For competitive inhibition, a perpendicular dropped to the negative x-axis from the point of intersection of the lines gives -Ki (Figure 812, top). For noncompetitive inhibition the intercept on the negative x-axis is -Ki (Figure 812, bottom). Pharmaceutical publications frequently employ Dixon plots to evaluate the comparative potency of competitive inhibitors. However, while the enzymeinhibitor complex can still bind substrate, its efficiency at transforming substrate to product, reflected by Vmax, is decreased. Noncompetitive inhibitors bind enzymes at sites distinct from the substrate-binding site and generally bear little or no structural resemblance to the substrate. The specificity and persistence of suicide inhibitors, which are both enzyme specific and unreactive outside the confines of the enzyme active site, render them promising leads for the development of enzyme-specific drugs. Neither the Lineweaver-Burk nor Dixon approach is applicable since suicide inhibitors violate a key boundary condition common to both approaches, namely that the activity of the enzyme does not decrease during the course of the assay. The fundamental principles discussed above, while illustrated for single-substrate enzymes, apply also to multisubstrate enzymes. The mathematical expressions used to evaluate multisubstrate reactions are, however, complex. While a detailed analysis of the full range of multisubstrate reactions exceeds the scope of this chapter, some common types of kinetic behavior for two-substrate, two-product reactions (termed "BiBi" reactions) are considered below. If so, this violates the assumption, implicit in classical steady-state kinetics, that the concentration of free inhibitor is independent of the concentration of enzyme. Sequential or Single-Displacement Reactions In sequential reactions, both substrates must combine with the enzyme to form a ternary complex before catalysis can proceed (Figure 813, top). Sequential reactions are sometimes referred to as single-displacement reactions because the group undergoing transfer is usually passed directly, in a single step, from one substrate to the other. Sequential Bi-Bi reactions can be further distinguished on the basis of whether the two substrates add in a random or in a compulsory order. One explanation for a compulsory-order mechanism is that the addition of A induces a conformational change in the enzyme that aligns residues that recognize and bind B. Irreversible Inhibitors "Poison" Enzymes In the above examples, the inhibitors form a dissociable, dynamic complex with the enzyme. Fully active enzyme can therefore be recovered simply by removing the inhibitor from the surrounding medium. However, a variety of other inhibitors act irreversibly by chemically modifying the enzyme. Since these covalent changes are relatively stable, an enzyme that has been "poisoned" by an irreversible inhibitor such as a heavy metal atom or an acylating reagent remains inhibited even after removal of the remaining inhibitor from the surrounding medium. Ping-Pong Reactions the term "ping-pong" applies to mechanisms in which one or more products are released from the enzyme before all the substrates have been added. Ping-pong reactions involve covalent catalysis and a transient, modified form of the enzyme (see Figure 74). The group undergoing transfer is first displaced from substrate A by the enzyme to form product P and a modified form of the enzyme (F). The subsequent Mechanism-Based Inhibition "Mechanism-based" or "suicide" inhibitors are specialized substrate analogs that contain a chemical group that can be transformed by the catalytic machinery of the target enzyme. Center: A random Bi-Bi reaction, characteristic of many kinases and some dehydrogenases. Bottom: A ping-pong reaction, characteristic of aminotransferases and serine proteases. An increase in concentration of one substrate (S1) while that of the other substrate (S2) is maintained constant changes both the x and y intercepts, but not the slope. Destroy or impair the growth, invasiveness, or development of invading pathogens 2. Most Bi-Bi Reactions Conform to Michaelis-Menten Kinetics Most Bi-Bi reactions conform to a somewhat more complex form of Michaelis-Menten kinetics in which Vmax refers to the reaction rate attained when both substrates are present at saturating levels. Each substrate has its own characteristic Km value, which corresponds to the concentration that yields half-maximal velocity when the second substrate is present at saturating levels. As for single-substrate reactions, doublereciprocal plots can be used to determine Vmax and Km. If the lines obtained for several fixed-substrate concentrations are plotted on the same graph, it is possible to distinguish between a ping-pong enzyme, which yields parallel lines, and a sequential mechanism, which yields a pattern of intersecting lines (Figure 814). Product inhibition studies are used to complement kinetic analyses and to distinguish between ordered and random Bi-Bi reactions. For example, in a random-order Bi-Bi reaction, each product will be a competitive inhibitor regardless of which substrate is designated the variable substrate. However, for a sequential mechanism (Figure 813, top), only product Q will give the pattern indicative of competitive inhibition when A is the variable substrate, while only product P will produce this pattern with B as the variable substrate. The other combi- By virtue of their diverse physiologic roles and high degree of substrate selectivity, enzymes constitute natural targets for the development of pharmacologic agents that are both potent and specific.
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma erectile dysfunction caused by radiation therapy purchase 80 mg top avana visa. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma erectile dysfunction after prostatectomy buy 80mg top avana free shipping. A prospective comparison of 18Ffluorodeoxyglucose positron emission tomography-computed tomography erectile dysfunction treatment chinese medicine discount 80 mg top avana fast delivery, magnetic resonance imaging and whole-body planar radiographs in the 245 yellow 5 impotence 80 mg top avana mastercard. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. High-dose therapy and autologous blood stem cell transplantation in multiple myeloma: preliminary results of a randomized trial involving 167 patients. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma. High-dose therapy autotransplantation/intensification vs continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Safety of autotransplants with highdose melphalan in renal failure: a pharmacokinetic and toxicity study. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Syngeneic transplantation in multiple myeloma-a case matched comparison with autologous and allogeneic transplantation. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. The exact incidence is unknown because many of these patients are assigned other diagnoses and therefore are not accurately represented in tumor registries. Patients in this heterogeneous group have a wide variety of clinical presentations and histologic tumor types. Most patients have metastatic carcinoma; however, many neoplasms are difficult to categorize using histologic features alone. At autopsy, primary sites (usually <2 cm in size) can be located in the majority of patients; the molecular basis of this unusual biologic behavior is undefined. At the time these regimens were developed, most types of solid tumors were poorly treated, and considerable overlap existed in the chemotherapy regimens used to treat sensitive tumor types. However, during the last 20 years, treatments have not only improved for many tumor types, but have also become more site specific. Therefore, the idea of providing optimal treatment to patients with a diverse group of solid tumors using a single chemotherapy regimen is no longer feasible. Situations in which results from the pathologic evaluation direct the clinical evaluation are addressed. Sarcoma and melanoma are also occasionally diagnosed without an obvious primary tumor site, and management of these patients follows established guidelines. These histologic diagnoses define patient groups that vary to some extent with respect to clinical characteristics, a recommended diagnostic evaluation, treatment, and prognosis. A fine-needle aspiration biopsy usually does not contain enough of a biopsy specimen for the necessary pathologic evaluation, and should not be performed as the initial diagnostic procedure. Close communication between the oncologist and pathologist is critical to ensure that the most important diagnostic studies are obtained with the available biopsy material.
The only way in which a free radical can be quenched erectile dysfunction after radical prostatectomy treatment options generic top avana 80 mg with visa, so terminating this chain reaction erectile dysfunction drugs market share generic 80mg top avana free shipping, is if two radicals react together erectile dysfunction doctors in ny purchase top avana 80mg with mastercard, when the unpaired electrons can become paired in one or other of the parent molecules erectile dysfunction treatment history 80mg top avana sale. This is a rare occurrence, because of the very short half-life of an individual radical and the very low concentrations of radicals in tissues. Tissue damage caused by oxygen radicals is often called oxidative damage, and factors that protect against oxygen radical damage are known as antioxidants. Radical damage to unsaturated fatty acids in cell membranes and plasma lipoproteins leads to the formation of lipid peroxides, then highly reactive dialdehydes that can chemically modify proteins and nucleic acid bases. Proteins are also subject to direct chemical modification by interaction with radicals. Oxidative damage to tyrosine residues in proteins can lead to the formation of dihydroxyphenylalanine that can undergo non-enzymic reactions leading to further formation of oxygen radicals. The total body radical burden can be estimated by measuring the products of lipid peroxidation. Under acidic conditions, they oxidize Fe2+ to Fe3+, which forms a chromophore with xylenol orange. Peroxidation of n-6 polyunsaturated fatty acids leads to the formation of pentane, and of n-3 polyunsaturated fatty acids to ethane, both of which can be measured in exhaled air. Chemical modification of amino acids in proteins, either by direct radical action or as a result of reaction with the products of radical-induced lipid peroxidation, leads to proteins that are recognized as non-self by the immune system. The resultant antibodies will also cross-react with normal tissue proteins, so initiating autoimmune disease. Tissue damage by filtrate under blood vessel endothelium (especially when there is already some damage to the endothelium), and are killed by the high content of unesterified cholesterol they have accumulated. This occurs in the development of atherosclerotic plaques which, in extreme cases, can more or less completely occlude a blood vessel. Transition metal ions, including Cu+, Co2+, Ni2+, and Fe2+ can react non-enzymically with oxygen or hydrogen peroxide, again leading to the formation of hydroxyl radicals. Nitric oxide (the endothelium- derived relaxation factor) is itself a radical, and, more importantly, can react with superoxide to yield peroxynitrite, which decays to form hydroxyl radicals. Plasma markers of radical damage to lipids increase considerably in response to even a mild infection. Sources Mitochondrial oxidation of reduced flavins chains proceeds through a series of steps in which the flavin semiquinone radical is stabilized by the protein to which it is bound, and forms oxygen radicals as transient intermediates. Although the final products are not radicals, because of the unpredictable nature of radicals there is considerable "leakage" of radicals, and some 35% of the daily consumption of 30 mol of oxygen by an adult human being is converted to singlet oxygen, hydrogen peroxide, and superoxide, perhydroxyl and hydroxyl radicals, rather then undergoing complete reduction to water. There Are Various Mechanisms of Protection Against Radical Damage the metal ions that undergo non-enzymic reaction to form oxygen radicals are not normally free in solution, but are bound to either the proteins for which they provide the pros- thetic group, or to specific transport and storage proteins, so that they are unreactive. Iron is bound to transferrin, ferritin and hemosiderin, copper to ceruloplasmin, and other metal ions are bound to metallothionein. This binding to transport proteins that are too large to be filtered in the kidneys also prevents loss of metal ions in the urine. Superoxide is produced both accidentally and also as the reactive oxygen species required for a number of enzyme-catalyzed reactions. A family of superoxide dismutases catalyze the reaction between superoxide and water to yield oxygen and - hydrogen peroxide: O2 + H2O O2 + H2O2. The hydrogen peroxide is then removed by catalase and various peroxidases: 2H2O2 2H2O + O2. Most enzymes that produce and require superoxide are in the peroxisomes, together with superoxide dismutase, catalase, and peroxidases. Lipid peroxides are also reduced to fatty acids by reaction with vitamin E, forming the relatively stable tocopheroxyl radical, which persist long enough to undergo reduction back to tocopherol by reaction with vitamin C at the surface of the cell or lipoprotein (Figure 446). The resultant monodehydroascorbate radical then undergoes enzymic reduction back to ascorbate or a non-enzymic reaction of 2 mol of monodehydroascorbate to yield 1 mol each of ascorbate and dehydroascorbate. Ascorbate, uric acid and a variety of polyphenols derived from plant foods act as water-soluble radical trapping antioxidants, forming relatively stable radicals that persist long enough to undergo reaction to non-radical products. Ubiquinone and carotenes similarly act as lipid-soluble radicaltrapping antioxidants in membranes and plasma lipoproteins. Antioxidants Can Also Be Pro-Oxidants Although ascorbate is an anti-oxidant, reacting with superoxide and hydroxyl to yield monodehydroascorbate and hydrogen peroxide or water, it can also be a source of superoxide radicals by reaction with oxygen, and hydroxyl radicals by reaction with Cu2+ ions (Table 45-1). However, these pro-oxidant actions require relatively high concentrations of ascorbate that are unlikely to be reached in tissues, since once the plasma concentration of ascorbate reaches about 30 mmol/L, the renal threshold is reached, and at intakes above about 100120 mg/day the vitamin is excreted in the urine quantitatively with intake. A considerable body of epidemiological evidence suggested that carotene is protective against lung and other cancers. However, two major intervention trials in the 1990s showed an increase in death from lung (and other) cancer among people given supplements of -carotene. The problem is that although -carotene is indeed a radical trapping antioxidant under conditions of low partial pressure of oxygen, as in most tissues, at high partial pressures of oxygen (as in the lungs) and especially in high concentrations, -carotene is an autocatalytic pro-oxidant, and hence can initiate radical damage to lipids and proteins. Epidemiological evidence also suggests that vitamin E is protective against atherosclerosis and cardiovascular disease. However, meta-analysis of intervention trials with vitamin E shows increased mortality among those taking (high dose) supplements. These trials have all used -tocopherol, and it is possible that the other vitamers of vitamin E that are present in foods, but not the supplements, may be important. In vitro, plasma lipoproteins form less cholesterol ester hydroperoxide when incubated with sources of low concentrations of perhydroxyl radicals when vitamin E has been removed than when it is present. The problem seems to be that vitamin E acts as an antioxidant by forming a stable radical that persists long enough to undergo metabolism to non-radical products. They can react with, and modify, proteins, nucleic acids and fatty acids in cell membranes and plasma lipoproteins. Radical damage to lipids and proteins in plasma lipoproteins is a factor in the development of atherosclerosis and coronary artery disease; radical damage to nucleic acids may induce heritable mutations and cancer; radical damage to proteins may lead to the development of auto-immune diseases. Oxygen radicals as a result of exposure to ionising radiation, non-enzymic reactions of transition metal ions, the respiratory burst of activated macrophages, and the normal oxidation of reduced flavin coenzymes. Protection against radical damage is afforded by enzymes that remove superoxide ions and hydrogen peroxide, enzymic reduction of lipid peroxides linked to oxidation of glutathione, non-enzymic reaction of lipid peroxides with vitamin E, and reaction of radicals with compounds such as vitamins C and E, carotene, ubiquinone, uric acid, and dietary polyphenols that form relatively stable radicals that persist long enough to undergo reaction to non-radical products. Except in people who were initially deficient, intervention trials of vitamin E and -carotene have generally shown increased mortality among those taking the supplements. Vitamin E forms a stable radical that is capable of either undergoing reaction with water-soluble antioxidants or penetrating further into lipoproteins and tissues, so increasing radical damage. Carr A, Frei B: Does vitamin C act as a pro-oxidant under physiological conditions? Various authors: Symposium: Antioxidant vitamins and -carotene in disease prevention. Various authors: Symposium Proceedings: Molecular Mechanisms of protective effects of vitamin E in atherosclerosis. Some are destined to be components of specific organelles, others for the cytosol or for export, and yet others will be located in the various cellular membranes. A major insight was the recognition by Blobel and others that for proteins to attain their proper locations, they generally contain information (a signal or coding sequence) that targets them appropriately. Once a number of the signals were defined (see Table 461), it became apparent that certain diseases result from mutations that affect these signals. In this chapter we discuss the intracellular traffic of proteins and their sorting and briefly consider some of the disorders that result when abnormalities occur. There they are directed to mitochondria, nuclei, and peroxisomes by specific signals-or remain in the cytosol if they lack a signal. Any protein that contains a targeting sequence that is subsequently removed is designated as a preprotein. In some cases a second peptide is also removed, and in that event the original protein is known as a preproprotein (eg, preproalbumin; Chapter 50). Certain other proteins destined for secretion are carried in secretory vesicles (Figure 462). Their mobilization and discharge are regulated and often referred to as "regulated secretion," whereas the secretory pathway involving transport vesicles is called "constitutive. Many proteins carry signals (usually but not always specific sequences of amino acids) that direct them to their destination, thus ensuring that they will end up in the appropriate membrane or cell compartment; these signals are a fundamental component of the sorting system. Usually the signal sequences are recognized and interact with complementary areas of other proteins that serve as receptors for those containing the signals. A major sorting decision is made early in protein biosynthesis, when specific proteins are synthesized either on free or on membrane-bound polyribosomes. First, it is involved in the processing of the oligosaccharide chains of membrane and other N-linked glycoproteins and also contains enzymes involved in O-glycosylation (see Chapter 47). Second, it is involved in the sorting of various proteins prior to their delivery to their appropriate intracellular destinations.
Generic top avana 80mg visa. Penis Tingles (an erection story).
References